Skip to main content
SpringerLink
Log in

Effect of Renal Disease on Pharmacokinetics and Bioavailability

  • Chapter
Chronic Renal Disease

Abstract

Therapeutically it is of vital importance to understand the pharmacokinetics and bioavailability of drugs, especially of those handled by the kidney. It would seem logical that with declining renal function, these functions might alter.

Supported by the Research and Development Service of the Veterans Administration and the Clinical Research Center of Northwestern University, RR-48, Division of Research Resources, National Institutes of Health.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dettli L: Individualization of drug dosage in patients with renal disease. Med Clin North Am 58:977–985, 1974.

    PubMed  CAS  Google Scholar 

  2. Dettli L, Spring P, Habersang R: Drug dosage in patients with impaired renal function. Postgrad Med J 46(suppl):32–35, 1970.

    Article  Google Scholar 

  3. Dettli L: Drug dosage in renal disease. Clin Pharmacokinet 1:126–134, 1976.

    Article  PubMed  CAS  Google Scholar 

  4. Koch-Weser J: Pharmacokinetics of procainamide in man. Ann NY Acad Sci 179:370–382, 1971.

    Article  PubMed  CAS  Google Scholar 

  5. Mark LC, Kayden HJ, Steele JM, Cooper JR, Berlin I, Rovenstine EA, Brodie BB: The physiological dispostion and cardiac effects of procainamide. J Pharmacol Exp Ther 102:5–15, 1951.

    PubMed  CAS  Google Scholar 

  6. Gibson TP, Matusik J, Matusik E, Nelson HA, Wilkinson J, Briggs WA: Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype. Clin Pharmacol Ther 17:395–399, 1975.

    PubMed  CAS  Google Scholar 

  7. Karlsson E, Molin L: Polymorphic acetylation of procainamide in healthy subjects. Acta Med Scand 197:299–302, 1975.

    Article  PubMed  CAS  Google Scholar 

  8. Gibson TP, Lowenthal DT, Nelson HA, Briggs WA: Elimination of procainamide in end stage renal failure. Clin Pharmacol Ther 17:321–329, 1975.

    PubMed  CAS  Google Scholar 

  9. Dreyfuss J, Bigger JT, Jr., Cohen AI, Schreiber EC: Metabolism of procainamide in rhesus monkey and man. Clin Pharmacol Ther 13:366–371, 1972.

    PubMed  CAS  Google Scholar 

  10. Reidenberg MM, Drayer DE, Levy M, Warner H: Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 17:722–730, 1975.

    PubMed  CAS  Google Scholar 

  11. Gibson TP, Atkinson AJ, Jr., Matusik E, Nelson LD, Briggs WA: Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney Int 12:422–429, 1977.

    Article  PubMed  CAS  Google Scholar 

  12. Scott Em, Wright RC: Fluorometric determination of isonicotinic acid hydrazide in serum. J Lab Clin Med 70:355–360, 1967.

    PubMed  CAS  Google Scholar 

  13. Matusik E, Gibson TP: Fluorometric assay for N-acetylprocainamide. Clin Chem 21:1899–1902, 1975.

    PubMed  CAS  Google Scholar 

  14. Giardina EV, Dreyfuss J, Bigger JT, Shaw JM, Schreiber EC: Metabolism of procainamide in normal and cardiac subjects. Clin Pharmacol Ther 19:339–351, 1976.

    PubMed  CAS  Google Scholar 

  15. Bowersox DW, Winterbauer RH, Stewart GL, Orme B, Barron E: Isoniazide dosage in patients with renal failure. N Engl J Med 289:84–87, 1973.

    Article  PubMed  CAS  Google Scholar 

  16. Reidenberg MM, Shear L, Cohen RV: Elimination of isoniazide in patients with impaired renal function. Am Rev Resp Dis 108:1426–1428, 1973.

    PubMed  CAS  Google Scholar 

  17. Dettli L, Spring P: in Okita GT, Acheson GH (eds): The Modifying Effects of Physiological Variables and Disease upon Pharmacokinetics—An Introduction. Basel, Karger, 1973, vol 3, pp 165–173.

    Google Scholar 

  18. Perrier D, Gibaldi M: Clearance and biologic half-life as indices of intrinsic hepatic metabolism. J Pharmacol Exp Ther 19:17–24, 1974.

    Google Scholar 

  19. Atkinson AJ, Jr., Lee W-K, Quinn ML, Cushner W, Nevin MJ, Strong JM: Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions. Clin Pharmacol Ther 21:575–587, 1977.

    PubMed  Google Scholar 

  20. Lee W-K, Strong JM, Kehoe RF, Dutcher JS, Atkinson AJ, Jr.: Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions. Clin Pharmacol Ther 19:508–514, 1976.

    PubMed  CAS  Google Scholar 

  21. Strong JM, Dutcher JS, Lee W-K, Atkinson AJ, Jr.: Pharmacokinetics in man of the N-acetylated metabolite of procainamide. J Pharmacokinet Biopharm 3:223–235, 1975.

    Article  PubMed  CAS  Google Scholar 

  22. Stec GP, Atkinson AJ, Jr., Nevin MJ, Thenot J-P, Ruo TI, Gibson TP, Ivanovich P, del Greco F: N-acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis. Clin Pharmacol Ther 26:618–628, 1979.

    PubMed  CAS  Google Scholar 

  23. Gibson TP, Matusik E, Briggs WA: N-acetylprocainamide levels in patients with end stage renal failure. Clin Pharmacol Ther 19:206–212, 1976.

    PubMed  CAS  Google Scholar 

  24. Goldstein A, Aronow L, Kaiman SM: Principles of Drug Actions: The Basis of Pharmacology. New York, Wiley, 1975, p 324.

    Google Scholar 

  25. Elson J, Strong JM, Lee W-K, Atkinson AJ, Jr.: Antiarrhythmic potency of N-acetylprocainamide. Clin Pharmcol Ther 17:134–140, 1975.

    CAS  Google Scholar 

  26. Koch-Weser J, Klein SW: Procainamide dosage schedules, plasma concentrations, and clinical effects. JAMA 215:1454–1460, 1971.

    Article  PubMed  CAS  Google Scholar 

  27. Dittert LW, Cressman WA, Kaplan SA, Riegelman S, Wagner JG: Guidelines for biopharmaceutical studies in man. Washington, D.C., American Pharmaceutical Association, Academy of Pharmaceutical Sciences, 1972, p 17.

    Google Scholar 

  28. Fordtran JS, Soergel HR, Ingelfinger FJ: Intestinal absorption of D-xylose in man. N Engl J Med 267:274–279, 1962.

    Article  PubMed  CAS  Google Scholar 

  29. Christiansen PA, Kirsner JB, Ablaya J: D-xylose and its use in the diagnosis of malabsorptive states. Am J Med 27:443–453, 1959.

    Article  PubMed  CAS  Google Scholar 

  30. Wyngaarden JB, Segal S, Foley JB: Physiological disposition and metabolic fate of infused pentoses in man. J Clin Invest 36:1395–1407, 1967.

    Article  Google Scholar 

  31. Butterworth CE, Perey-Santiago E, Martinez de Jesus J, Santiri R: Studies on the oral and parenteral administration of D-xylose. N Engl J Med. 261:157–161, 1959.

    Article  PubMed  Google Scholar 

  32. Finlay JM, Hogarth J, Nightman KJR: A clinical evaluation of the D-xylose tolerance test. Ann Intern Med 61:411–422, 1964.

    PubMed  CAS  Google Scholar 

  33. Hoeney MR, Culank LS, Montgomery RD, Sarmmous HG: Evaluation of xylose absorption as measured in blood and urine. A one hour blood xylose screening test in malabsorption. Gastroenterology 75:393–400, 1978.

    Google Scholar 

  34. Craig RM, Murphy P, Gibson TP, Quintanilla A, Chao GC, Cochrane C, Patterson A, Athinson AJ Jr.: Kinetic analysis of D-xylose absorption in normal subjects and in patients with chronic renal failure. J Lab Clin Med 101:496–506, 1893.

    Google Scholar 

  35. Roe JH, Rice EW: A photometric method for the determination of free pentoses in animal tissues. J Biol Chem 173:507–512, 1948.

    PubMed  CAS  Google Scholar 

  36. Segal S, Foley JB: The metabolism of C14 labeled pentoses in man. J Clin Invest 38:407–413, 1959.

    Article  PubMed  CAS  Google Scholar 

  37. Huguenin P, Cochet B, Balant L, Loizeau ED: Test d’absorption du D-xylose. Schweiz Med Wschr 108:206–214, 1978.

    PubMed  CAS  Google Scholar 

  38. Quintanilla A, Craig R, Gibson T, Shambaugh G: Glucose metabolism in uremia. Am J Clin Nutr 33:1446–1450, 1980.

    PubMed  CAS  Google Scholar 

  39. Tilstone WJ, Fine A: Furosemide kinetics in renal failure. Clin Pharmacol Ther 23:644–650, 1978.

    PubMed  CAS  Google Scholar 

  40. Chau NP, Weiss YA, Safara ME, Lavene DE, Georges DR, Milliez PL: Pindolol availability in hypertensive patients with normal and impaired renal function. Clin Pharmacol Ther 22:505–510, 1977.

    PubMed  CAS  Google Scholar 

  41. Simenhoff ML: Metabolism and toxicity of aliphatic amines. Kidney Int 7:5314–5317, 1975.

    Google Scholar 

  42. Toshes PP, King CE, Spivey JC, Lorenz E: Xylose catabolism in the experimental rat blind loop syndrome. Gastroenterology 74:691–697, 1978.

    Google Scholar 

  43. Wagner JC: Biopharmaceutics: Absorption aspects. J Pharm Sci 50:359–387, 1961.

    Article  PubMed  CAS  Google Scholar 

  44. Grodstein G, Harrison A, Roberts C, Ippoliti A, Kopple J: Impaired gastric emptying in hemodialysis patients. Am Soc Neph 12:82A, 1979.

    Google Scholar 

  45. Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G: Pharmacokinetics of D-propoxyphine in anephric patients. Clin Pharmacol Ther 21:103, 1977.

    Google Scholar 

  46. Wood AJJ, Vestal RE, Spannath C, Stone WJ, Wilkinson GR, Shand DG: Propranolol disposition in renal failure. Clin Res 27:239A, 1979.

    Google Scholar 

  47. Galeazzi RL, Gugger M, Weidmann P: Beta blockade with pindolol: Differential cardiac and renal effects despite similar plasma kinetics in normal and uremic man. Kidney Int 15:661–668, 1979.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Nephrology/Hypertension and Department of Medicine, Northwestern University Medical School, Northwestern Memorial Hospital, USA

    Thomas P. Gibson

  2. Veterans Administration Lakeside Medical Center, Chicago, Illinois, 60611, USA

    Thomas P. Gibson

Authors
  1. Thomas P. Gibson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Washington University School of Medicine, St. Louis, Missouri, USA

    Saulo Klahr M.D.

  2. National Institutes of Health, Bethesda, Maryland, USA

    Nancy Boucot Cummings M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Plenum Publishing Corporation

About this chapter

Cite this chapter

Gibson, T.P. (1985). Effect of Renal Disease on Pharmacokinetics and Bioavailability. In: Cummings, N.B., Klahr, S. (eds) Chronic Renal Disease. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4826-9_40

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-4826-9_40

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-4828-3

  • Online ISBN: 978-1-4684-4826-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation